基于模型的A型肉毒神经毒素对肌肉收缩抑制的跨物种解释
Hyo-Jeong Ryu1,2, Seongsung Kwak1, Misun Park1
1Department of Pharmacology and Toxicology, Gwangyo R&D Center, Medytox Inc., Suwon, South Korea.
Biopharmaceutics & drug disposition
|July 20, 2024
概括
这项研究开发了一种动力学 - 药理学 (K-PD) 模型,用于分析来自动物上毒神经毒素A型 (BoNT/A) 研究的肌肉反应数据. 该模型有助于预测BoNT/A效应,并将动物数据与人类反应联系起来.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 生物数学是生物数学.
背景情况:
- 肉毒神经毒素 (BoNTs),特别是BoNT类型A (BoNT/A),广泛用于治疗和化品.
- 精确评估血液中的BoNT/A具有挑战性,需要使用药理动力学 (PD) 标记物,如复合肌动力潜力 (CMAP) 和数字绑架得分 (DAS).
研究的目的:
- 在BoNT/A产品开发过程中开发一种概率动力学-药理学 (K-PD) 模型,用于解释动物模型中的CMAP和DAS数据.
- 了解模型参数与动物模型对人类反应的推断之间的关系.
主要方法:
- 利用癌症研究所的雌性小鼠和斯普拉格-道利大鼠,在BoNT/A给药后的32周内测量CMAP和DAS.
- 开发了一个肌肉收缩抑制模型,其中包含一个虚拟药理动力学 (PK) 分区和一个间接响应模型.
- 执行严格的模型诊断,包括适合性,视觉预测检查 (VPC) 和引导分析.
主要成果:
- 根据CMAP和DAS的分析,与BoNT/A的使用有明显的剂量依赖关系.
- 根据使用的BoNT/A剂量观察到不同的恢复时间.
- 开发的K-PD模型有效地描述了实验数据,并揭示了特定物种的PK和PD参数差异.
结论:
- 该研究成功地确定了K-PD建模对于理解BoNT/A效应的实用性.
- 该模型为未来的研究和将发现推断到其他BoNT/A产品和潜在的人类应用提供了基础.
相关概念视频
Neuromuscular Junction And Blockade
3.0K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
3.0K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
665
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
665
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Classification of Skeletal Muscle Relaxants
2.4K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.4K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
406
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
406
Muscle Contraction
90.5K
90.5K


